[HTML][HTML] Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
J Wang, C Liu, R Hu, L Wu, C Li - Frontiers in Pharmacology, 2024 - frontiersin.org
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and
accounts for more than 90% of primary liver cancer. The advent of immune checkpoint …
accounts for more than 90% of primary liver cancer. The advent of immune checkpoint …
Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
J Wang, C Liu, R Hu, L Wu, C Li - Frontiers in Pharmacology, 2024 - europepmc.org
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and
accounts for more than 90% of primary liver cancer. The advent of immune checkpoint …
accounts for more than 90% of primary liver cancer. The advent of immune checkpoint …
Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
J Wang, C Liu, R Hu, L Wu, C Li - Frontiers in …, 2024 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and
accounts for more than 90% of primary liver cancer. The advent of immune checkpoint …
accounts for more than 90% of primary liver cancer. The advent of immune checkpoint …
[引用][C] Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
J Wang, C Liu, R Hu, L Wu, C Li - Frontiers in Pharmacology (Web), 2024 - jglobal.jst.go.jp
Abou-AlfaG. K., ChanS. L., KudoM., LauG., KelleyR. K., FuruseJ., et al (2022). Phase 3
randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first …
randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first …
[HTML][HTML] Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
J Wang, C Liu, R Hu, L Wu, C Li - Frontiers in Pharmacology, 2024 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and
accounts for more than 90% of primary liver cancer. The advent of immune checkpoint …
accounts for more than 90% of primary liver cancer. The advent of immune checkpoint …
Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma.
J Wang, C Liu, R Hu, L Wu, C Li - Frontiers in Pharmacology, 2024 - europepmc.org
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and
accounts for more than 90% of primary liver cancer. The advent of immune checkpoint …
accounts for more than 90% of primary liver cancer. The advent of immune checkpoint …